Monitor the BDR v. FDA lawsuit closely; any ruling that narrows or vacates the GAIN Act exclusivity extension would be a material negative catalyst for PHAT. The case is at the complaint stage — next key events are the FDA's response and any motion to dismiss. A settlement or early dismissal would remove the overhang.
Price Chart
Executive Summary
Phathom disclosed that BDR Pharmaceuticals has sued the FDA challenging the agency's refusal to accept an ANDA referencing VOQUEZNA (vonoprazan fumarate), arguing the FDA improperly applied the GAIN Act to extend Phathom's NCE exclusivity. Phathom believes the FDA correctly granted 10 years of NCE exclusivity through May 3, 2032, and intends to defend it. This litigation introduces binary risk to the exclusivity timeline for VOQUEZNA, Phathom's sole marketed product.
Key Facts
- BDR Pharmaceuticals filed suit against the FDA in U.S. District Court for D.C., challenging the FDA's refusal to receive an ANDA referencing VOQUEZNA.
- BDR alleges the FDA improperly applied the GAIN Act to extend Phathom's NCE exclusivity for VOQUEZNA (vonoprazan fumarate) tablets.
- Phathom states the FDA granted its Citizen Petition on June 6, 2025, recognizing 10 years of NCE exclusivity for VOQUEZNA tablets through May 3, 2032.
- Phathom intends to take appropriate action to protect its statutory exclusivities.
- An adverse outcome could reduce the exclusivity period and allow ANDA approvals earlier than currently anticipated.
Financial Impact
VOQUEZNA is Phathom's only marketed product; loss of exclusivity before May 2032 would expose the franchise to generic competition, potentially eliminating the majority of the company's revenue stream. No specific revenue or market size figures were provided in the filing.
Risk Factors
- BDR could succeed in its challenge, reducing NCE exclusivity and allowing generic ANDA approvals years earlier than May 2032.
- Litigation may be lengthy, costly, and distract management; adverse public perception could pressure the stock and VOQUEZNA sales.
- Phathom may be unable to maintain non-patent regulatory exclusivity for VOQUEZNA for the expected duration.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-430621 |
| Document: 0001193125-26-430621-index-headers.html | 0001193125-26-430621 |
| Document: 0001193125-26-430621-index.html | 0001193125-26-430621 |
| Document: 0001193125-26-430621.txt | 0001193125-26-430621 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 8-K | $5.94 $5.99 | ▼ −0.84% | ▼ −0.28% | $5.99 (−0.84%) |
Oct 23, 2026 4d ago | 8-K | $5.94 $5.99 | ▼ −0.84% | ▼ −0.28% | $5.99 (−0.84%) |
Oct 19, 2026 8d ago | Press Release | $7.01 | awaiting T+1 | — | $5.99 (−14.55%) |
Sep 29, 2026 28d ago | 8-K | $7.30 $7.08 | ▼ −3.01% | ▼ −3.19% | $5.99 (−17.95%) |
Jul 30, 2026 12w ago | 8-K | $9.03 $8.75 | ▼ −3.10% | ▼ −3.81% | $5.99 (−33.67%) |
Jul 30, 2026 12w ago | Press Release | $9.03 $8.75 | ▲ +3.10% | ▲ +3.81% | $5.99 (+33.67%) |
Jul 20, 2026 14w ago | Press Release | $10.65 | awaiting T+1 | — | $5.99 (−43.76%) |
May 20, 2026 22w ago | Press Release | $11.87 $11.58 | ▼ −2.44% | ▼ −2.64% | $5.99 (−49.54%) |
May 1, 2026 25w ago | Press Release | $12.01 $12.87 | ▲ +7.16% | ▲ +7.50% | $5.99 (−50.12%) |
Apr 30, 2026 25w ago | Press Release | $11.20 $12.01 | ▲ +7.23% | ▲ +7.01% | $5.99 (−46.52%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers